Transcatheter arterialization of the deep veins for chronic limb-threatening ischemia in no-option patients kept most ...

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and ...

Phase 2 clinical trial underway with first patient dosed in October to support a clear path to Phase 3 based on previous alignment with FDA ...

The Prayer Shawl Ministry, for anyone who enjoys knitting or crocheting, is looking for folks who enjoy making prayer shawls and squares, baby blankets and hats to minister to others. Yarn is provided ...

BOOST Pharma, a clinical-stage cell biotech company focused on rare skeletal pediatric diseases, is proud to announce that new long-term data from the first-in-class BOOSTB4 stem cell therapy trial ...

Takeda tightened its pipeline in the third quarter. Innovent Biologics reported a head-to-head win against semaglutide in a Chinese phase 3 trial. | Takeda tightened its pipeline in the third quarter.

Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study- Cash burn of $4.2 million in Q3 remains in line with ...

In a new series of special reports, our partner First News – the UK’s only newspaper specifically for young people – has ...

This news is covered by the Medical Dialogues Bureau present at the TCT Conference 2025, being held in San Francisco, USA.The ...

Sharing Our Story challenged young Pittsburghers to share their voices and diverse identities through digital storytelling.

OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and nine months ended September 30, 2025. Highlights from ...

It was a mild autumn day along the Missouri River. Chris and Angie Long — the two people who, more than any others, are on a ...